Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Insulin aspart (NovoLog PenFill)

<u>Initiation (new start) criteria</u>: Non-formulary **insulin aspart (Novolog PenFill) or its unbranded biologic** will be covered on the prescription drug benefit when the following criteria are met:

Meets 1 of the following criteria:

- Diagnosis of Type 2 diabetes mellitus with a documented allergy or intolerance* to regular insulin AND insulin lispro
- Diagnosis of Type 1 diabetes mellitus or Type 2 diabetes mellitus with insulinopenia[^]
 with a documented allergy or intolerance^{*} to insulin lispro

-AND-

Meets 1 of the following criteria:

- Unable to draw up insulin accurately from a vial with a syringe due to young age, visual impairment, physical disabilities (i.e., amputations, tremors/Parkinson's disease, rheumatoid arthritis), or history of IV drug use
- Pediatric patient who is required to use such devices by school
- Type 1 diabetes mellitus

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary **insulin aspart**(Novolog PenFill) or its unbranded biologic will be covered on the prescription drug benefit when the following criteria are met:

Meets 1 of the following criteria:

- Diagnosis of Type 2 diabetes mellitus with a documented allergy or intolerance* to regular insulin AND insulin lispro
- Diagnosis of Type 1 diabetes mellitus or Type 2 diabetes mellitus with insulinopenia[^]
 with a documented allergy or intolerance^{*} to insulin lispro

kp.org

Revised: 04/14/22 Effective: 06/02/22 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



^{*} Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

[^] Insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Insulin aspart (NovoLog PenFill)

-AND-


Meets 1 of the following criteria:

- Unable to draw up insulin accurately from a vial with a syringe due to young age, visual impairment, physical disabilities (i.e., amputations, tremors/Parkinson's disease, rheumatoid arthritis), or history of IV drug use
- Pediatric patient who is required to use such devices by school
- Type 1 diabetes mellitus

^ Insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.

kp.org

Revised: 04/14/22 Effective: 06/02/22





^{*} Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation